All In Biotech

Drug Trial Radar · NCT06914128

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Jun 18, 2029

Study completion Jun 18, 2029

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses. Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse. The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase. Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems. Participants will visit the study site: * at least twice before the treatment starts * multiple times when they start taking the treatment * once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason During the study, the doctors and their study team will: * check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram * check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan * take tumor samples The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

Conditions

  • MTAP-deleted Solid Tumors

Interventions

  • BAY 3713372Drug

    Daily oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
  2. Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
  3. Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
  4. Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
  5. Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
  6. Dose Escalation (Master and Intervention Cohort 1): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)
  7. Dose Escalation (Master and Intervention Cohort 1): Area under the curve (AUC) of the respective dosing interval of BAY 3713372Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)
  8. Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)Time frame: Approximately 1.5 years
  9. Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
  10. Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
  11. Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention
  12. Intervention Cohort 7: Number of participants with DLTsTime frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
  13. Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372Time frame: From first dose through day of surgery (approximately 7 ± 2 days)
  14. Intervention Cohort 7: Tumor tissue SDMA levelsTime frame: From first dose through day of surgery (approximately 7 ± 2 days)

Locations

62 sites in 13 countries. Site status is shown where the registry gives one.

  • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama · Not yet recruiting

  • City of Hope - Duarte Cancer Center

    Duarte, California · Not yet recruiting

  • UCLA Health Bowyer Oncology Center

    Los Angeles, California · Not yet recruiting

  • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology

    San Francisco, California · Recruiting

  • Stanford University Medical Center - Neurology

    Stanford, California · Not yet recruiting

  • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center

    Aurora, Colorado · Not yet recruiting

  • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's

    Denver, Colorado · Recruiting

  • Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona

    Orlando, Florida · Recruiting

  • Massachusetts General Hospital - Neurology

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute - Oncology Department

    Boston, Massachusetts · Not yet recruiting

  • START | Midwest

    Grand Rapids, Michigan · Recruiting

  • Icahn School of Medicine at Mount Sinai - Oncology

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center New York - Main Campus

    New York, New York · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • NEXT Dallas - Oncology Department

    Irving, Texas · Recruiting

  • START | San Antonio

    San Antonio, Texas · Recruiting

  • Froedtert Hospital - Clinical Cancer Center

    Milwaukee, Wisconsin · Not yet recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre

    Concord, New South Wales, Australia · Recruiting

  • Northern Hospital

    Epping, New South Wales, Australia · Not yet recruiting

  • Calvary Mater Hospital Newcastle - Oncology

    Waratah, New South Wales, Australia · Recruiting

  • Antwerp University Hospital | Oncology Department

    Antwerp, Antwerp, Belgium · Recruiting

  • Ghent University Hospital | Drug Research Unit Department

    Ghent, East Flanders, Belgium · Recruiting

  • UZ Leuven Gasthuisberg - Pneumology Department

    Leuven, Flemish Brabant, Belgium · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology

    Liège, Liège, Belgium · Recruiting

  • Beijing Cancer Hospital - Oncology Department

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing chest hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.

    Wuhan, Hubei, China · Recruiting

  • Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Fakultní nemocnice Olomouc - Onkologická klinika

    Olomouc, Olomouc Region, Czechia · Recruiting

  • Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)

    Brno, South Moravian, Czechia · Recruiting

  • Rigshospitalet Copenhagen University Hospital | Oncology Department

    Copenhagen, Capital Region / Region Hovedstaden, Denmark · Recruiting

  • Odense University Hospital | Svendborg Sygehus - Oncology Department

    Odense, Region of Southern Denmark / Region Syddanmark, Denmark · Recruiting

  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati

    Aviano, Friuli Venezia Giulia, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I

    Rome, Lazio, Italy · Recruiting

  • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione

    Rome, Lazio, Italy · Not yet recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1

    Milan, Lombardy, Italy · Recruiting

  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia

    Rozzano, Lombardy, Italy · Recruiting

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan · Not yet recruiting

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.